CD38 and graft versus host disease: Interestingly, the use of daratumumab, an FDA approved monoclonal antibody against CD38, in a cohort of 34 multiple myeloma patients after allo-HSCT resulted in low aGvHD (15%) and no cGvHD, suggesting that CD38 is an attractive target for the treatment of GvHD (7).